The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend stability. Click here to read.

A second magnificent ultra-high-yield dividend stock that's begging to be bought in November is pharmaceutical titan Pfizer ( ...

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions. Merck has a 3.7% yield and a lot of leeway to protect its dividend. Some of the largest drugmakers in ...

You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

S&P 500 gained 1.5 per cent, while the Nasdaq Composite gained 2.26 per cent, to 23,524.82. Read more at straitstimes.com.

Days after the Supreme Court appeared skeptical of the legal backing for many of his tariffs, the president on social media Sunday lauded the revenue they have brought in and said the government would ...